OR (95% CI) | P values | Adjusted OR (95% CI) | P values | |
Treatment group | ||||
Hospitalised | 1.0 | 1.0 | ||
Community | 1.09 (0.70 to 1.68) | 0.71 | 1.0 (0.63 to 1.60) | 0.99 |
Sex | ||||
Female | 1.0 | 1.0 | ||
Male | 0.80 (0.51 to 1.27) | 0.35 | 0.67 (0.41 to 1.09) | 0.11 |
Age | ||||
<44 | 1.0 | 1.0 | ||
≥44 | 0.53 (0.34 to 0.83) | 0.006 | 0.40 (0.24 to 0.67) | <0.001 |
Resistance pattern | ||||
INH+RIF or GXP/RIF | 1.0 | 1.0 | ||
INH+RIF+ | 1.20 (0.78 to 1.85) | 0.41 | 1.15 (0.73 to 1.83) | 0.54 |
XDR | 0.31 (0.04 to 2.27) | 0.25 | 0.28 (0.04 to 2.23) | 0.23 |
HIV | ||||
Negative | 1.0 | 1.0 | ||
Positive | 0.47 (0.29 to 0.78) | 0.003 | 0.33 (0.19 to 0.64) | <0.001 |
Baseline BMI | ||||
≥16 | 1.0 | 1.0 | ||
<16 | 0.41 (0.26 to 0.64) | <0.001 | 0.40 (0.25 to 0.64) | <0.001 |
BMI, body mass index; GXP, GeneXpert MTB/RIF; INH, isoniazid; INH+RIF+, additional drug resistance beyond INH and RIF, not XDR; MDR, multidrug resistant; RIF, rifampicin; XDR, extensively drug-resistant TB.